Curis, Inc. (CRIS) Reports In-Line Q1 Loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Curis' (CRIS) Q1 Results Flat; Erivedge Growth, Pipeline Remain in Focus - Roth
May 8, 2014 2:18 PM EDTRoth Capital comments on Curis, Inc. (Nasdaq: CRIS) following the company's Q1 report, which was out ahead of the bell Thursday. Briefly, Curis posted an in-line loss of 8 cents per share.
Analyst Joseph Pantginis commented, After the FDA removed the partial clinical hold on the Phase I CUDC-427 monotherapy study in March, CRIS is preparing to re-open the study under the amended protocol. CRIS plans to initiate... More
